Trevena, Inc. (TRVN)
OTCMKTS
· Delayed Price · Currency is USD
1.830
-0.030 (-1.61%)
Jan 21, 2025, 4:00 PM EST
Trevena Revenue
Trevena had revenue of $283.00K in the quarter ending September 30, 2024, with 57.22% growth. This brings the company's revenue in the last twelve months to $546.00K, down -82.97% year-over-year. In the year 2023, Trevena had annual revenue of $3.13M, down -847.61%.
Revenue (ttm)
546.00K
Revenue Growth
-82.97%
P/S Ratio
2.67
Revenue / Employee
23.74K
Employees
23
Market Cap
1.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.13M | 3.54M | -847.61% |
Dec 31, 2022 | -418.00K | -985.00K | -173.72% |
Dec 31, 2021 | 567.00K | -2.50M | -81.52% |
Dec 31, 2020 | 3.07M | 3.04M | 9,800.00% |
Dec 31, 2019 | 31.00K | -5.70M | -99.46% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |
Trevena News
- 2 months ago - Trevena Reports Third Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Trevena receives Nasdaq delisting notification - Seeking Alpha
- 3 months ago - Trevena Announces Receipt of Nasdaq Delisting Notification - GlobeNewsWire
- 7 months ago - Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing - GlobeNewsWire
- 7 months ago - What's Going On With Neurological Disease Focused Trevena On Thursday? - Benzinga
- 7 months ago - Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models - GlobeNewsWire
- 9 months ago - Trevena Reports First Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update - GlobeNewsWire